CareLit · DOI-Nachweis · Pneumologie
A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
DOI 10.1055/s-0031-1272244
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, J Harvey, D Spigel, M Dediu, M Reck, C Cebotaru, E Kumm, G Gallant, N Fox, D Camidge
ZeitschriftPneumologie
Ausgabe03/2011
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: Mapatumumab, a fully human agonist mab, targets and activates the death receptor TRAIL-R1. We conducted a randomized, controlled phase II trial to evaluate mapatumumab in combination with carboplatin and paclitaxel as first-line therapy in advanced non-small call lung cancer (NSCLC). Methods: Patients were required to have histol. or cytol. confirmed Stage IIIB or IV advanced primary NSCLC with measurable dise…
Zitieren
Zitierempfehlung
J von Pawel, J Harvey, D Spigel, M Dediu, M Reck, C Cebotaru, E Kumm, G Gallant, N Fox, D Camidge (2011) A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC. Pneumologie (03). https://doi.org/10.1055/s-0031-1272244
Mit CareLit weiterarbeiten